Late-stage study supports Herceptin in combination with hormonal therapy
According to the company, hormone receptor-positive breast cancer affects two-thirds of patients with breast cancer and is typically considered 'lower-risk' due to successful treatment with hormonal therapies. However,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.